GlassScriptPhysician profile
William R Lewis
NPI 1942282801
$8,294.93
in general payments reported to CMS, 2019-2025
25 companies · $774 in 2025
The $774 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,073 · 2020: $593 · 2021: $266 · 2022: $511 · 2023: $586 · 2024: $1,491 · 2025: $774.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,851.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,851.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,115.61 | 2019-2025 | Xience Skypoint, Dragonfly Opstar, Mitraclip |
| E.R. Squibb & Sons, L.L.C. | $1,008.19 | 2019-2025 | Camzyos, Eliquis |
| Biotronik INC. | $842.42 | 2019-2024 | Acticor 7 Vr-T Dx, Amvia Edge |
| Shockwave Medical, INC | $740.97 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $545.62 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $406.42 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $362.71 | 2024-2025 | Winrevair |
| Amgen INC. | $306.34 | 2019-2023 | Repatha |
| Boston Scientific Corporation | $264.34 | 2019-2020 | |
| Pfizer INC. | $242.14 | 2019-2023 | |
| Kestra Medical Technology Services, INC. | $175.44 | 2024 | Assure Wcd |
| Novartis Pharmaceuticals Corporation | $166.34 | 2019-2025 | |
| Heartflow, INC. | $135.48 | 2020 | |
| Portola Pharmaceuticals, LLC | $135.45 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $130.15 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $127.85 | 2019-2024 | |
| Alnylam Pharmaceuticals INC. | $124.72 | 2019 | |
| Abiomed | $123.97 | 2019 | |
| Philips North America LLC | $123.12 | 2023 | |
| Ge Healthcare | $89.18 | 2019-2023 | |
| Chiesi USA, INC. | $46.69 | 2019-2020 | |
| Edwards Lifesciences Corporation | $24.38 | 2025 | Pascal |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.83 | 2019 | |
| Sanofi-Aventis U.S. LLC | $20.73 | 2019 | |
| Acarix USA INC. | $15.84 | 2024 | Cadscor System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.